Anbio Biotechnology (NNNN) stock
NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$3.32−0.33 (-9.04%)
Close on Nov 20, 2026Market cap $477.72MP/E 22.6Yield –
Anbio Biotechnology gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $7.54M, up 28.2% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.54M | +28.2% |
| FY2024 | Dec 31, 2024 | $5.89M | +75.1% |
| FY2023 | Dec 31, 2023 | $3.36M | -73.2% |
| FY2022 | Dec 31, 2022 | $12.56M | – |
See a number that looks wrong?